The use of neutralizing antibodies to demonstrate the role of transforming growth factor-beta and Amadori-glycated albumin as mediators of experimental diabetic kidney disease.
Ziyadeh
F N
FN
Renal-Electrolyte and Hypertension Division, University of Pennsylvania, School of Medicine, Philadelphia, USA.
Sharma
K
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003928:Diabetic Nephropathies / Q000209:etiology*; D017127:Glycation End Products, Advanced; D006801:Humans; D012709:Serum Albumin / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000502:physiology*; D000093423:Glycated Serum Albumin
D000911:Antibodies, Monoclonal; D017127:Glycation End Products, Advanced; D012709:Serum Albumin; D016212:Transforming Growth Factor beta; D000093423:Glycated Serum Albumin